<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905744/" ref="ordinalpos=4761&amp;ncbi_uid=2362134&amp;link_uid=PMC2905744" image-link="/pmc/articles/PMC2905744/figure/F3/" class="imagepopup">Figure 3. The Phosphatidylinsoitol-3 kinase (PI3K)-Akt <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>.  From: Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. </a></div><br /><div class="p4l_captionBody">PI3K is activated by binding of growth factors (GF) to a receptor tyrosine kinase (RTK) through direct interaction or adapter molecules. PIP2 is then phosphorylated by PI3K to form PIP3, which then engages Akt and PDK1 resulting in phosphorylation of Akt (either directly or by PDK1). Activated Akt then stimulates pathways involved in cell growth and protein synthesis (mTOR), activates pro-survival molecules (NF-ÎºB), and inhibits pro-apoptotic molecules (FOXO, Bad, p53) thereby promoting cell survival and proliferation. PTEN negatively regulates PI3K-Akt signaling.</div></div>